We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Trends in Metabolites Predict Mortality for Hospitalized Patients

By LabMedica International staff writers
Posted on 17 Aug 2017
Patients who are hospitalized for an extensive period are at risk for adverse outcomes and are likely to have a high mortality rate than those who have shorter stays.

These long-term hospitalized patients often rapidly deteriorate leading to death, with cause of death attributable to different factors like sepsis and end organ damage.

Scientists at the SUNY Downstate Medical Center (Brooklyn, NY, USA) evaluate end of life laboratory values time trends among deceased long-term inpatients. More...
They extracted time stamped laboratory data for deceased adult inpatients that had died in hospital from all-cause mortality between January 2014 and December 2016. All adult deceased patients who were hospitalized for at least one week were included in the study. Statistical analysis included an autoregressive integrated moving average (ARIMA) model.

The investigators evaluated laboratory results from 110 patients. The average length of hospitalization prior to death was 12.3 days. Significant time trends that were observed included increases in blood urea nitrogen (BUN), aspartate aminotransferase (AST) and alanine aminotransferase (ALT). The Mann-Kendall trend test showed that there is an upward trend in BUN and liver function tests indicative of end organ damage. Sodium, chloride and potassium levels are stationary over time; however, in the last 48 hours of life the metabolites become unstable with values varying from the expected value by more than one standard deviation.

The authors concluded that in the last 48 hours of life in chronically morbid hospitalized patients an alteration of the physiologic state of the patient occurs which manifests as subtle changes in metabolite levels especially when compared to the long-term result trends of the patient. Perhaps early detection of these changes can allow for timely interventions for the patients. The study was presented at the 69th Annual meeting of American Association for Clinical Chemistry held August 1–3, 2017, in San Diego, CA, USA.

Related Links:
SUNY Downstate Medical Center


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.